Developer docs
API playgroundTry for free, no card

Search company profiles

Rex Bionics

Full company profile

uuid0006gu2

Namestring
Rex Bionics
Legal namestring
Rex Bionics Ltd
Websiteurl
rexbionics.com
Company typeenum
Public
Founded yearint
2007
Descriptiontext

Rex Bionics designs, manufactures, and commercializes the REX, a hands-free, self-supporting robotic exoskeleton intended for people with lower-limb weakness or paralysis arising from spinal cord injury, multiple sclerosis, stroke, traumatic brain injury, cerebral palsy, and related neurological conditions. The device is built around ten custom linear actuators supporting users up to 100 kg, a custom carbon-fibre pelvis and cuffs, a rechargeable lithium-polymer battery delivering roughly 60 minutes of use, and a proprietary motion-control stack comprising half a million lines of code distributed across 27 onboard microprocessors. The REX differs from competing exoskeletons (e.g., ReWalk, Ekso) in that it requires no crutches, leaving the user's arms free for upper-body exercise and activities of daily living, and is therefore usable by patients with impaired upper-body function, including tetraplegics and high-level stroke patients.

The company's core commercial offering is the REX hardware sold as a capital purchase to rehabilitation centers, hospitals, and spinal-cord-injury clinics, complemented by the REXERCISES branded set of structured, physiotherapist-designed exercise programs. Rex Bionics operates a direct-sales model with regional offices in Auckland (HQ), Melbourne, and Boston, and distributor partnerships covering China (Maxhealth Medical Group, pending CFDA approval; MAAB Group) and the Middle East (Armana Healthcare). Clinical validation has been pursued through a multi-year trial program including RAPPER II (spinal cord injury, 56 patients), RAPPER III and RAPPER IV (multiple sclerosis, East Kent Hospitals with NIHR), and HELLEN (stroke and brain injury, AIN with University of Newcastle). Reported outcomes include pain reduction from 9/10 to 4/10 'worst pain' in case data, 90% improvement in a 'felt physically tense at night' sleep measure, and 94% of trial volunteers indicating willingness to use REX weekly.

Rex Bionics was incorporated in New Zealand in 2007, previously listed on the AIM market of the London Stock Exchange under ticker RXB (now delisted), and operates through wholly-owned subsidiaries in Australia and the United States. Pricing of the REX device is not publicly disclosed and is handled via direct contact with regional offices; market data for comparable medical exoskeletons places per-unit pricing in the USD 70,000-150,000 range. The company is led by CEO Crispin Simon, with General Manager Tracey White supporting operations and former CEO Dr Charles Carignan having led the firm during earlier clinical-trial phases.

Short descriptiontext

Rex Bionics manufactures REX, a hands-free robotic exoskeleton used by rehabilitation centers and hospitals to provide standing, walking, and exercise therapy for patients with spinal cord injury, multiple sclerosis, stroke, and other neurological conditions causing lower-limb weakness or paralysis.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersAuckland, New Zealand
HQ citystring
Auckland
HQ countrystring
New Zealand
HQ regionstring
Oceania
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
robotic rehabilitation devices, medical exoskeletons, mobility assistance technology, neurological rehabilitation equipment, hands-free exoskeleton
Industry4 codes
PRIMARYHDAAAIAC
Healthcare & Assistive Robotics
SECONDARYHLAHAMAG
Rehabilitation Therapy Equipment (PT/OT Modalities, Exercise & Balance Devices)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Rehabilitation & Mobility Aids (DME)
SECONDARYHSADAIAN
Prosthetics/Orthotics Rehab & Amputee Rehabilitation
Home & Personal Services/Fitness, Wellness & Personal Training/Physical Therapy, Rehabilitation & Corrective Exercise
SECONDARYHLAHAMAJ
Sports & Active Rehabilitation Devices (Adaptive Sports Mobility, Performance Prosthetics)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Rehabilitation & Mobility Aids (DME)
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Offices of Physical, Occupational and Speech Therapists, and Audiologists62134
SIC code2 codes
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Medical Rehabilitation Robotics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1REX Device Sales
TypeHardware Sales
Description

Sale of REX robotic rehabilitation devices to rehabilitation centers, hospitals, and healthcare facilities. The device is a capital purchase requiring significant investment.

rexbionics.com
2Clinical/Professional Services
TypeProfessional Services
Description

Training and support services for healthcare professionals using REX in clinical settings

rexbionics.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales
Pricing details1 tier
1REX Rehabilitation Device
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

No public pricing available - sales handled through direct contact with regional offices in US, UK, Australia, New Zealand

rexbionics.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1REXERCISES
Description

Brand name for the robot-assisted physiotherapy exercise programs developed by Rex Bionics in collaboration with physical therapists

rexbionics.com
+1 more record
Core offering1 text field

Rex Bionics designs, manufactures, and sells the REX, a hands-free, self-supporting, independently controlled robotic exoskeleton that enables standing, walking, and structured exercise for people with lower limb weakness or paralysis arising from spinal cord injury, stroke, multiple sclerosis, cerebral palsy, and other neurological conditions. The company sells the REX device primarily to rehabilitation centers, hospitals, and clinical facilities as a capital purchase, complemented by training and clinical support services, with associated structured exercise programs (REXERCISES) developed by specialist physiotherapists.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Six out of eight sleep indicators showed improvement after a single REX treatment in RAPPER II trial
+4 more records
Product overview1 text field

Rex Bionics offers a single unified product portfolio centered on the REX robotic rehabilitation device. The REX is a hands-free exoskeleton that enables standing, walking, and exercise for people with mobility impairments. The companion REXERCISES program provides structured exercise protocols designed by physiotherapists for use within the REX system. The company operates as a medical device manufacturer with operations in New Zealand (headquarters), Australia, USA, and distribution partnerships in China and the Middle East.

Product and service1 record
1REX Robotic Rehabilitation Device
CategoryRehabilitation Robotics Hardware
Description

A hands-free, self-supporting, independently controlled robotic exoskeleton that provides standing, walking, and exercise support for people with lower limb weakness or paralysis, including those with spinal cord injury (complete or incomplete), multiple sclerosis, stroke, cerebral palsy, traumatic brain injury, or other neurological conditions. The device supports users up to 100kg, accommodates users from approximately 4'8" to 6'4" in height, and is sold primarily to rehabilitation centers, hospitals, and clinical facilities as a capital purchase.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2019-06-01
Description

CSP encouraged participants for the RAPPER IV MS Trial, promoting awareness of the clinical research program.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-01-01
Description

Partnership for RAPPER III and RAPPER IV clinical trials evaluating REX for multiple sclerosis patients. Led by Dr Mohammed Sakel, Director of Neurorehabilitation service. Supported by NIHR (National Institute for Health Research).

3Kent University
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2017-01-01
Description

Academic partnership with East Kent Hospitals for RAPPER III MS clinical trial.

rexbionics.com
4NHS National Institute for Health Research (NIHR)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-01-01
Description

Provided ethics committee approval for RAPPER III clinical trial in multiple sclerosis.

rexbionics.com
5Australian Institute of Neuro-rehabilitation (AIN)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2016-10-01
Description

Conducts clinical trials treating patients who have had a stroke or brain injury with Robot-Assisted Physiotherapy with REX. Ethics clearance through Hunter New England Human Research Ethics Committee. Collaboration with University of Newcastle.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2016-10-01
Description

Research partner with AIN for stroke and brain injury clinical trials using REX device. Supported by The Newcastle Permanent Charitable Foundation.

7The Newcastle Permanent Charitable Foundation
Strategic tierMinorTypeOthersAnnounced on2016-10-01
Description

Funding support for the HELLEN research trial using REX for stroke and brain injury rehabilitation.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Exclusive distributor partnership in China for REX devices. Device not yet available pending approval from CFDA (China Food and Drug Administration). Contact: maxhealth@imaxhealth.com

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Partnership Agreement for China market distribution (mentioned in media section).

10EmergoEurope
Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

Listed as contact for UK & Europe regulatory/distribution support.

rexbionics.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers8 records
1Bionik Laboratories
TypeEmerging player
Description

Bionik Laboratories develops the InMotion ARM and ARTHUR robotic therapy devices for upper and lower limb rehabilitation in clinical settings. While its product line focuses more on end-effector robotics than full exoskeletons, it competes for the same rehabilitation centre capex budgets that fund REX sales.

TypeEmerging player
Description

Wandercraft has developed the Atalante self-balancing lower-limb exoskeleton for stroke and SCI rehabilitation, positioning it as a hands-free alternative in the same way REX does. It represents an emerging peer with overlapping product philosophy in the EU/US rehabilitation market.

3Hocoma (part of DIH Medical)
TypeBroad incumbent
Description

Hocoma, now part of DIH Medical, is an established robotic-rehabilitation vendor with Lokomat (gait trainer) and Armeo (upper-limb) products widely used in hospitals. It is a broad incumbent that competes for rehabilitation centre budgets but does not offer a free-standing exoskeleton like REX.

TypeDirect peer
Description

Cyberdyne's HAL (Hybrid Assistive Limb) is one of the most established lower-limb exoskeletons for rehabilitation and personal use, with strong adoption in Japan and Europe. HAL competes for the same hospital and SCI/Stroke patient indications as REX, though it is also crutch-based.

TypeDirect peer
Description

Ekso Bionics is a direct competitor in the rehab exoskeleton market with the EksoGT, used in hospitals and rehabilitation centres for stroke and SCI patients. It targets the same B2B clinical channel as Rex Bionics but uses a crutch-based design, making REX's hands-free approach a key point of differentiation.

6Honda Walking Assist Device
TypeBroad incumbent
Description

Honda's Walking Assist Device is a partial lower-limb exoskeleton primarily aimed at gait training in clinical and aged-care settings. It overlaps with REX on the rehab-stance indication and competes with broader incumbents in Japan and parts of Asia.

TypeDirect peer
Description

ReWalk is a direct competitor offering both personal and rehabilitation exoskeletons (ReWalk Personal 6.0 and ReStore) for SCI and stroke patients. Like Ekso, ReWalk relies on crutch-based balance, contrasting with REX's hands-free stance; the companies compete directly for hospital capex budgets.

TypeDirect peer
Description

Indego, developed by Parker Hannifin, is a modular lower-limb exoskeleton used in rehabilitation centres for SCI and stroke patients in the US. It is a direct competitor to REX in terms of clinical channel, patient indication, and use case.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers9 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Rex Bionics

Medical Rehabilitation Roboticsrexbionics.com

Rex Bionics manufactures REX, a hands-free robotic exoskeleton used by rehabilitation centers and hospitals to provide standing, walking, and exercise therapy for patients with spinal cord injury, multiple sclerosis, stroke, and other neurological conditions causing lower-limb weakness or paralysis.

What Rex Bionics does

Rex Bionics designs, manufactures, and commercializes the REX, a hands-free, self-supporting robotic exoskeleton intended for people with lower-limb weakness or paralysis arising from spinal cord injury, multiple sclerosis, stroke, traumatic brain injury, cerebral palsy, and related neurological conditions. The device is built around ten custom linear actuators supporting users up to 100 kg, a custom carbon-fibre pelvis and cuffs, a rechargeable lithium-polymer battery delivering roughly 60 minutes of use, and a proprietary motion-control stack comprising half a million lines of code distributed across 27 onboard microprocessors. The REX differs from competing exoskeletons (e.g., ReWalk, Ekso) in that it requires no crutches, leaving the user's arms free for upper-body exercise and activities of daily living, and is therefore usable by patients with impaired upper-body function, including tetraplegics and high-level stroke patients.

The company's core commercial offering is the REX hardware sold as a capital purchase to rehabilitation centers, hospitals, and spinal-cord-injury clinics, complemented by the REXERCISES branded set of structured, physiotherapist-designed exercise programs. Rex Bionics operates a direct-sales model with regional offices in Auckland (HQ), Melbourne, and Boston, and distributor partnerships covering China (Maxhealth Medical Group, pending CFDA approval; MAAB Group) and the Middle East (Armana Healthcare). Clinical validation has been pursued through a multi-year trial program including RAPPER II (spinal cord injury, 56 patients), RAPPER III and RAPPER IV (multiple sclerosis, East Kent Hospitals with NIHR), and HELLEN (stroke and brain injury, AIN with University of Newcastle). Reported outcomes include pain reduction from 9/10 to 4/10 'worst pain' in case data, 90% improvement in a 'felt physically tense at night' sleep measure, and 94% of trial volunteers indicating willingness to use REX weekly.

Rex Bionics was incorporated in New Zealand in 2007, previously listed on the AIM market of the London Stock Exchange under ticker RXB (now delisted), and operates through wholly-owned subsidiaries in Australia and the United States. Pricing of the REX device is not publicly disclosed and is handled via direct contact with regional offices; market data for comparable medical exoskeletons places per-unit pricing in the USD 70,000-150,000 range. The company is led by CEO Crispin Simon, with General Manager Tracey White supporting operations and former CEO Dr Charles Carignan having led the firm during earlier clinical-trial phases.

Rex Bionics firmographics

Firmographics
Name
Rex Bionics
Legal name
Rex Bionics Ltd
Website
https://rexbionics.com
Company type
Public
Founded year
2007
Operating status
Operating
Headcount range
11–50 employees
Short description
Rex Bionics manufactures REX, a hands-free robotic exoskeleton used by rehabilitation centers and hospitals to provide standing, walking, and exercise therapy for patients with spinal cord injury, multiple sclerosis, stroke, and other neurological conditions causing lower-limb weakness or paralysis.
Ownership category
akta.pro rank

Rex Bionics industry classification

Industry
Product category
Medical Rehabilitation Robotics
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Offices of Physical, Occupational and Speech Therapists, and Audiologists (62134)
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHDAAAIAC
Healthcare & Assistive Robotics
SECONDARYHLAHAMAG
Rehabilitation Therapy Equipment (PT/OT Modalities, Exercise & Balance Devices)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Rehabilitation & Mobility Aids (DME)
SECONDARYHSADAIAN
Prosthetics/Orthotics Rehab & Amputee Rehabilitation
Home & Personal Services/Fitness, Wellness & Personal Training/Physical Therapy, Rehabilitation & Corrective Exercise
SECONDARYHLAHAMAJ
Sports & Active Rehabilitation Devices (Adaptive Sports Mobility, Performance Prosthetics)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Rehabilitation & Mobility Aids (DME)

Keywords

  • Robotic rehabilitation devices
  • Medical exoskeletons
  • Mobility assistance technology
  • Neurological rehabilitation equipment
  • Hands-free exoskeleton

Where Rex Bionics is headquartered

Location

Headquarters

HQ city
Auckland
HQ country
New Zealand
HQ region
Oceania

Offices3 records

Markets served

Rex Bionics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. REX Device Sales: Sale of REX robotic rehabilitation devices to rehabilitation centers, hospitals, and healthcare facilities. The device is a capital purchase requiring significant investment.
  2. Clinical/Professional Services: Training and support services for healthcare professionals using REX in clinical settings

Pricing tiers

ModelBillingPrice
One time/ perpetual licensePay-as-you-goREX Rehabilitation Device

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Rex Bionics product offering

Product offering

Core offering

Rex Bionics designs, manufactures, and sells the REX, a hands-free, self-supporting, independently controlled robotic exoskeleton that enables standing, walking, and structured exercise for people with lower limb weakness or paralysis arising from spinal cord injury, stroke, multiple sclerosis, cerebral palsy, and other neurological conditions. The company sells the REX device primarily to rehabilitation centers, hospitals, and clinical facilities as a capital purchase, complemented by training and clinical support services, with associated structured exercise programs (REXERCISES) developed by specialist physiotherapists.

Product overview

Rex Bionics offers a single unified product portfolio centered on the REX robotic rehabilitation device. The REX is a hands-free exoskeleton that enables standing, walking, and exercise for people with mobility impairments. The companion REXERCISES program provides structured exercise protocols designed by physiotherapists for use within the REX system. The company operates as a medical device manufacturer with operations in New Zealand (headquarters), Australia, USA, and distribution partnerships in China and the Middle East.

Differentiator

Problem solved

Functional benefit

Brands

  • REXERCISES: Brand name for the robot-assisted physiotherapy exercise programs developed by Rex Bionics in collaboration with physical therapists
  • REX

Products and services

  • REX Robotic Rehabilitation Device A hands-free, self-supporting, independently controlled robotic exoskeleton that provides standing, walking, and exercise support for people with lower limb weakness or paralysis, including those with spinal cord injury (complete or incomplete), multiple sclerosis, stroke, cerebral palsy, traumatic brain injury, or other neurological conditions. The device supports users up to 100kg, accommodates users from approximately 4'8" to 6'4" in height, and is sold primarily to rehabilitation centers, hospitals, and clinical facilities as a capital purchase.

Quantifiable outcome

  • Six out of eight sleep indicators showed improvement after a single REX treatment in RAPPER II trial
  • +4 more outcomes

Companies that use Rex Bionics

Customer profile

Named customers9 records

Segments3 records

Ideal customer profiles2 records

Rex Bionics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Rex Bionics partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered minor and core.

  • Chartered Society of Physiotherapists (CSP)minorGTM or Marketing Partner · 1 June 2019CSP encouraged participants for the RAPPER IV MS Trial, promoting awareness of the clinical research program.
  • East Kent Hospitals University NHS Foundation TrustcoreStrategic or Co-development Partner · 1 January 2017Partnership for RAPPER III and RAPPER IV clinical trials evaluating REX for multiple sclerosis patients. Led by Dr Mohammed Sakel, Director of Neurorehabilitation service. Supported by NIHR (National Institute for Health Research).
  • Kent UniversityminorStrategic or Co-development Partner · 1 January 2017Academic partnership with East Kent Hospitals for RAPPER III MS clinical trial.
  • NHS National Institute for Health Research (NIHR)coreStrategic or Co-development Partner · 1 January 2017Provided ethics committee approval for RAPPER III clinical trial in multiple sclerosis.
  • Australian Institute of Neuro-rehabilitation (AIN)coreStrategic or Co-development Partner · 1 October 2016Conducts clinical trials treating patients who have had a stroke or brain injury with Robot-Assisted Physiotherapy with REX. Ethics clearance through Hunter New England Human Research Ethics Committee. Collaboration with University of Newcastle.
  • University of Newcastle, AustraliacoreStrategic or Co-development Partner · 1 October 2016Research partner with AIN for stroke and brain injury clinical trials using REX device. Supported by The Newcastle Permanent Charitable Foundation.
  • The Newcastle Permanent Charitable FoundationminorOthers · 1 October 2016Funding support for the HELLEN research trial using REX for stroke and brain injury rehabilitation.
  • Maxhealth Medical Group Co. LtdcoreChannel Partner/ Reseller/ DistributorExclusive distributor partnership in China for REX devices. Device not yet available pending approval from CFDA (China Food and Drug Administration). Contact: maxhealth@imaxhealth.com
  • MAAB GroupcoreChannel Partner/ Reseller/ DistributorPartnership Agreement for China market distribution (mentioned in media section).
  • EmergoEuropeminorImplementation/ SI/ Consulting PartnerListed as contact for UK & Europe regulatory/distribution support.

Scale indicators3 records

Recent moves6 records

Expansion highlights7 records

Rex Bionics competitors and assessment

Company assessment

Emerging players

  • Bionik Laboratories: Bionik Laboratories develops the InMotion ARM and ARTHUR robotic therapy devices for upper and lower limb rehabilitation in clinical settings. While its product line focuses more on end-effector robotics than full exoskeletons, it competes for the same rehabilitation centre capex budgets that fund REX sales.
  • Wandercraft: Wandercraft has developed the Atalante self-balancing lower-limb exoskeleton for stroke and SCI rehabilitation, positioning it as a hands-free alternative in the same way REX does. It represents an emerging peer with overlapping product philosophy in the EU/US rehabilitation market.

Broad incumbents

  • Hocoma (part of DIH Medical): Hocoma, now part of DIH Medical, is an established robotic-rehabilitation vendor with Lokomat (gait trainer) and Armeo (upper-limb) products widely used in hospitals. It is a broad incumbent that competes for rehabilitation centre budgets but does not offer a free-standing exoskeleton like REX.
  • Honda Walking Assist Device: Honda's Walking Assist Device is a partial lower-limb exoskeleton primarily aimed at gait training in clinical and aged-care settings. It overlaps with REX on the rehab-stance indication and competes with broader incumbents in Japan and parts of Asia.

Direct peers

  • Cyberdyne: Cyberdyne's HAL (Hybrid Assistive Limb) is one of the most established lower-limb exoskeletons for rehabilitation and personal use, with strong adoption in Japan and Europe. HAL competes for the same hospital and SCI/Stroke patient indications as REX, though it is also crutch-based.
  • Ekso Bionics: Ekso Bionics is a direct competitor in the rehab exoskeleton market with the EksoGT, used in hospitals and rehabilitation centres for stroke and SCI patients. It targets the same B2B clinical channel as Rex Bionics but uses a crutch-based design, making REX's hands-free approach a key point of differentiation.
  • ReWalk Robotics: ReWalk is a direct competitor offering both personal and rehabilitation exoskeletons (ReWalk Personal 6.0 and ReStore) for SCI and stroke patients. Like Ekso, ReWalk relies on crutch-based balance, contrasting with REX's hands-free stance; the companies compete directly for hospital capex budgets.
  • Parker Hannifin (Indego): Indego, developed by Parker Hannifin, is a modular lower-limb exoskeleton used in rehabilitation centres for SCI and stroke patients in the US. It is a direct competitor to REX in terms of clinical channel, patient indication, and use case.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Rex Bionics social profiles

Digital presence

Rex Bionics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Rex Bionics leadership team

Management profile

Number of profiles

Profiles2 records

Rex Bionics subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Rex Bionics funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Rex Bionics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rex Bionics

What does Rex Bionics do?

Rex Bionics designs, manufactures, and sells the REX, a hands-free, self-supporting, independently controlled robotic exoskeleton that enables standing, walking, and structured exercise for people with lower limb weakness or paralysis arising from spinal cord injury, stroke, multiple sclerosis, cerebral palsy, and other neurological conditions. The company sells the REX device primarily to rehabilitation centers, hospitals, and clinical facilities as a capital purchase, complemented by training and clinical support services, with associated structured exercise programs (REXERCISES) developed by specialist physiotherapists.

Is Rex Bionics a public or private company?

Rex Bionics is a public company. It is classified as public and is currently operating.

When was Rex Bionics founded?

Rex Bionics was founded in 2007. It employs 11 to 50 people.

Where is Rex Bionics based?

Rex Bionics is headquartered in Auckland, New Zealand, in the Oceania region.

How does Rex Bionics make money?

Two revenue lines are on record. REX Device Sales are the primary driver. The others are clinical/Professional Services.

Who are Rex Bionics's main competitors?

Emerging players on record are Bionik Laboratories and Wandercraft. Broad incumbents are Hocoma (part of DIH Medical) and Honda Walking Assist Device. Direct peers are Cyberdyne, Ekso Bionics, ReWalk Robotics and Parker Hannifin (Indego).

Does Rex Bionics have an API?

No public API is recorded for Rex Bionics.

What industry is Rex Bionics in?

Rex Bionics's product category is Medical Rehabilitation Robotics. Its primary akta.pro industry code is HDAAAIAC, Healthcare & Assistive Robotics, with a secondary code of HLAHAMAG, Rehabilitation Therapy Equipment (PT/OT Modalities, Exercise & Balance Devices). Its NAICS code is 334510 and its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Dealroom.coRex Bionics raises tens of millions of yuan to expand rehab robots globally | Dealroom NewsRex Bionics, a Wuxi-based rehabilitation robot maker, raised tens of millions of yuan in a strategic round led by Huada Songhe with Meian Innovation joining. The funds will support global commercialization and product development, including clinical studies in the US and Europe. The company's self-balancing exoskeleton holds EU CE and US FDA certification.PrtimesRehabilitation Robots Market Set to Reach US$ 16.88 Billion by 2033 – PR TimesBusiness Market Insights published a market research report projecting the global rehabilitation robots market to grow from US$7.72 billion in 2025 to US$16.88 billion by 2033, representing a compound annual growth rate of 10.27%. Key growth drivers include the rising global burden of neurological disorders and orthopedic injuries, aging populations, and technological advancements in AI, machine learning, and wearable robotics, with North America currently leading adoption. The competitive landscape includes companies such as CYBERDYNE INC., Lifeward (ReWalk Robotics), Ekso Bionics, Hocoma, Rex Bionics Ltd., and others actively investing in product development and geographic expansion.GlobeNewswireRehabilitation Robots Market Analysis Report 2025-2030, Featuring Profiles of Tyromotion, Hocoma, Rex Bionics, Kinova, Rehab-Robotics, ReWalk Robotics, Ekso Bionics, Cyberdyne and Bionik LaboratoriesThe global rehabilitation robots market is projected to reach USD 1.03 billion by 2030, growing at a 15.2% CAGR from 2025 to 2030. Lower-body exoskeletons held the largest revenue share in 2024, while hospitals and clinics accounted for 47.1% of the market. North America led with 45.1% share, and Asia Pacific is expected to grow fastest.YahooRehabilitation Robots Market Analysis Report 2025-2030, Featuring Profiles of Tyromotion, Hocoma, Rex Bionics, Kinova, Rehab-Robotics, ReWalk Robotics, Ekso Bionics, Cyberdyne and Bionik LaboratoriesResearchAndMarkets.com added a 120-page report on the global rehabilitation robots market, covering type, extremity, end-use and regional forecasts through 2030. The market is estimated at USD 428 million in 2024 and USD 1.03 billion by 2030, a 15.2% CAGR. Lower-body exoskeletons and hospitals & clinics led 2024 shares, while Asia Pacific is expected to grow fastest.ExportertodayNZ’s Rex Bionics gets $1.63 mln funding liftRex Bionics, a New Zealand company that developed a robotic exoskeleton for wheelchair users, has secured an additional $1.63 million in funding from TechNZ to develop a second version. This funding will be matched by Rex Bionics, allowing the company to simultaneously work on its existing product while advancing the new version to maintain its competitive edge in the market. Richard Bentley from TechNZ emphasized the importance of sustained investment for innovative firms like Rex Bionics to retain market leadership.CNETRobotic legs give the paralyzed a new view of their worldArthur Renowitzky, paralyzed since 2007, walks with a ReWalk exoskeleton suit, raising $80,000 via crowdfunding. The suit helps paraplegics regain mobility, with companies like Ekso Bionics citing improved oxygen consumption and reduced complications. Researchers aim for lighter, thought-controlled suits.CBS NewsRobotic legs give the paralyzed a new view of their worldParalyzed individuals use motorized exoskeletons to walk, with ReWalk and Indigo costing $80,000 each. The suits help patients improve mobility and reduce complications, but only a handful have regulatory approval for home use. Researchers aim to make them lighter and more intuitive.The GuardianBionic legs and smart slacks: exoskeletons that could enhance us allExoskeletons like Rex Bionics' £80,000 device enable paraplegic users to walk, with about 40 in use worldwide. Researchers are developing lighter, smarter versions, including smart trousers and inflatable braces, aiming for commercial devices within two decades.CNETParaplegic’s post-college gig: Testing bionic legsAustin Whitney, a UC Berkeley graduate, spends six hours daily testing a custom exoskeleton developed by Berkeley Bionics. The device, which he walked in at his graduation, is expected to be available to rehabilitation centers by year-end, with a personal version for sale in 2013.CNET1st Rex commercial bionic legs go to ParalympianRex Bionics sold its first commercial robotic exoskeleton to Paralympian Dave MacCalman, who paid $150,000 for the device. The 84-pound exoskeleton lets him walk up stairs and reach tall shelves, and he took his first steps in over 30 years. The company says the legs will become smaller and less awkward over time.